Dr. Vakil Takhaveev is a Lecturer at ETH Zurich's Department of Health Sciences and Technology, within the Institute of Food, Nutrition and Health. His research focuses on DNA damage mechanisms, aging, cancer, and neurodegeneration, with particular emphasis on developing novel DNA-damage-sequencing methods like click-code-seq and TRABI-Seq . He investigates anticancer drug action (e.g., trabectedin), aging clocks using DNA oxidation profiling, and stress-induced carcinogenesis. His work integrates multi-omics approaches and advanced sequencing techniques. Research Directions: Novel DNA-Damage-Sequencing Methods: Developed click-code-seq and TRABI-Seq for genomic mapping of DNA lesions and repair dynamics. Anticancer Drug Action: Explored mechanisms of trabectedin and other chemotherapeutics, linking DNA repair vulnerabilities to therapy resistance. Aging Clocks: Created DNA oxidation-based biomarkers for biological aging using genome-wide profiling in human and mouse models. Stress-Induced Pathologies: Studies metabolic and DNA damage links to early tumorigenesis and neurodegeneration. Awards & Recognition: 2025 Public Award Winner in PIs of Tomorrow competition 2024 ETH Zurich Career Seed Award Best presentation awards (Swiss Chemical Society, American Chemical Society) Grants & Collaborations: Impetus grants for aging clock development Swiss Chemical Society and American Chemical Society fellowships Labs & Teams: Leads research on DNA damage and aging mechanisms at ETH Zurich, collaborating with international groups in oncology and toxicology.
Wengong Jin is an Assistant Professor at the Khoury College of Computer Sciences, Northeastern University, and a visiting research scientist at the Eric and Wendy Schmidt Center at the Broad Institute. He holds a PhD from MIT CSAIL, advised by Prof. Regina Barzilay and Prof. Tommi Jaakkola. Research Interests: His work focuses on geometric and generative AI models for drug discovery, biology, and chemical engineering. Key areas include equivariant neural networks (e.g., FAFormer), diffusion models for binding energy prediction, antibody/enzyme design (RefineGNN, SurfPro), and molecular design through graph neural networks (Junction Tree VAE). He also explores domain generalization and systems for autonomous molecular discovery. Publications: His research has been published in top venues like NeurIPS, ICLR, ICML, Nature, Science, and Cell. Recent breakthroughs include discovering novel antibiotics using explainable AI and designing synergistic drug combinations for cancer treatment. Awards: He has received the BroadIgnite Award, Dimitris N. Chorafas Prize, and MIT EECS Outstanding Thesis Award for his contributions to computational biology and AI-driven drug discovery. Teaching: Currently teaches a PhD seminar on AI for Science, focusing on integrating machine learning into scientific discovery processes.
Connor Coley is the Henri Slezynger (1957) Career Development Assistant Professor at the Massachusetts Institute of Technology (MIT) School of Engineering. His research bridges chemistry and machine learning, focusing on autonomous molecular discovery, predictive chemistry, and laboratory automation. Education: Ph.D., MIT (2019) M.S.CEP., MIT (2016) B.S., Caltech (2014) Research Interests: Dr. Coley’s work centers on domain-informed machine learning for chemistry, computer-aided molecular design, and autonomous laboratories. Key themes include predictive modeling of chemical reactivity, optimization of synthesis pathways, and integration of AI with experimental data for drug discovery and materials science. Publications: His recent articles highlight advancements in AI-driven reaction prediction, molecular representation learning, and laboratory automation. Trends include applications of Bayesian optimization, contrastive learning, and diffusion models to chemical discovery. Scientific Awards: Camille Dreyfus Teacher-Scholar Award (2025) James W. Swan Outstanding Faculty (2025) Schmidt Futures AI2050 Early Career Fellow (2022) NSF CAREER Award (2021) Forbes 30 Under 30: Healthcare (2019) Software & Tools: He leads the open-source ASKCOS software suite for synthesis planning, adopted by 35,000+ chemists and deployed at 15+ pharmaceutical companies. His team also develops tools for metabolomics and molecular representation learning.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
Karen C. Cheung is a Professor in the Department of Electrical and Computer Engineering at the University of British Columbia, with cross-appointments in the Faculty of Medicine and the School of Biomedical Engineering where she serves as Director of the Graduate Program. She holds her office in KAIS 3064 and can be reached at (604) 827-4114. Dr. Cheung received her BSc and PhD degrees in Bioengineering from the University of California, Berkeley in 1998 and 2002, respectively. From 2002-2005, she was a postdoctoral researcher at the École Polytechnique Fédérale de Lausanne in Switzerland. She joined UBC in 2006 and has established herself as a leading researcher in biomedical microsystems. Her research spans multiple areas of biomedical engineering with particular focus on lab-on-a-chip systems for cell culture and characterization , inkjet printing for tissue engineering , and implantable neural interfaces . Her work integrates microfluidics, biosensors, and tissue engineering to create platforms that better mimic in vivo conditions for drug screening and disease modeling. Current projects include developing organ-on-a-chip models of the human airway for studying aerosol exposure effects, creating microscale tumor models for cancer research, and advancing silicon photonic biosensors for medical diagnostics. Dr. Cheung leads the Bio-Medical Micro Devices Laboratory at UBC, which houses multiple research teams working on cutting-edge biomedical technologies. Her lab has developed microfluidic platforms capable of precisely controlling oxygen levels around tumor spheroids to study cancer treatment responses under realistic physiological conditions. The lab also works on novel fabrication techniques for microelectrode arrays and tissue clearing protocols for 3D imaging of microtissues. As an educator, Dr. Cheung teaches several specialized courses including ELEC 361 (Molecules to Mechanisms), ELEC 464 (Nanotechnology and Nature), EECE 301 (Topics in Nanotechnology and Microsystems), ELEC 473 (Biological Micro-Electro-Mechanical Systems), and ELEC 521 (Biomedical Microdevices). She has supervised numerous graduate students through their MASc, PhD, and postdoctoral work, with many alumni now holding academic positions or working in the biomedical industry. Her research is supported through multiple funding sources and collaborations with industry partners. Dr. Cheung is affiliated with several research centers including the Airway Centre, Bionics Network, Centre for Blood Research, and the Institute for Computing, Information and Cognitive Systems (ICICS) at UBC.
David R. Koes is an Associate Professor in the Department of Computational and Systems Biology at the University of Pittsburgh, affiliated with the School of Medicine. He holds roles such as Associate Director of the Joint CMU-Pitt Computational Biology PhD Program (CPCB) and is involved in multiple graduate programs including Intelligent Systems and Computational Biomedicine. His research focuses on developing computational algorithms and systems for drug discovery, emphasizing open-source software and machine learning applications in biomedical data. Koes teaches courses like MSCBIO2025 (Bioinformatics Programming in Python) and MSCBIO2065 (Scalable Machine Learning for Big Data Biology). He has secured NIH funding (R35GM140753) and collaborated on projects with institutions like NVIDIA and Google Cloud. His lab develops tools such as GNINA, Pharmit, and 3Dmol.js, and actively contributes to open drug discovery initiatives. Education: PhD in Computer Science from Carnegie Mellon University (CMU). Research Interests: Leveraging computation and AI for drug design, molecular docking, pharmacophore modeling, and open science. Specific areas include developing scalable machine learning pipelines, virtual screening systems, and tools for 3D molecular analysis. Grants and Funding: Current NIH R35 grant and prior support from NSF, Relay Therapeutics, and others. His work emphasizes translating computational methods into practical drug discovery solutions. Lab and Teams: Directs a lab focused on computational drug discovery, collaborating with multiple academic and industry partners. Supervises graduate students and postdocs in projects spanning AI-driven drug design, molecular modeling, and software development.
Charles E. Leonard is an Associate Professor of Epidemiology at the Perelman School of Medicine , University of Pennsylvania. He holds affiliations with multiple Penn-based institutions, including the Center for Real-World Effectiveness and Safety of Therapeutics (CREST), Institute for Translational Medicine and Therapeutics, Leonard Davis Institute, Institute on Aging, and Center of Excellence in Environmental Toxicology. Additionally, he serves as a Special Government Employee at the FDA and Honorary Lecturer at Muhimbili University of Health and Allied Sciences in Tanzania. Pharmacoepidemiology Post-market prescription drug safety Causal inference methods Real-world evidence generation Environmental health impacts on chronic disease Dr. Leonard’s research focuses on generating real-world evidence to address critical gaps in drug safety, particularly for: Population health effects of drug interactions Comparative safety of antidiabetes drugs Drug-induced sudden cardiac arrest Ambient temperature extremes and chronic disease Pharmacoepidemiology methods development His work is primarily funded by the National Institutes of Health (NIH) and has been recognized through multiple awards, including the 2024 Harold I. Feldman Distinguished Scholar Award and the 2020 Elected Fellow status at the International Society for Pharmacoepidemiology. He also contributes to curriculum development and student mentoring in Penn’s Graduate Group in Epidemiology and Biostatistics. 2024 – Harold I. Feldman Distinguished Scholar Award (Penn) 2024 – Ronald D. Mann Best Paper Award (ISPE) 2020 – Leadership Medallion (BPS) 2019 – Abraham G. Hartzema Distinguished Lecturer (University of Florida)
David S. Eisenberg is a Professor of Chemistry and Biochemistry and Biological Chemistry at the University of California, Los Angeles, where he also serves as Director of the UCLA-DOE Institute for Genomics and Proteomics and as an HHMI Investigator. His research focuses on protein interactions, particularly the structural basis for conversion of normal proteins to the amyloid state and conversion of prions to the infectious state. Dr. Eisenberg earned his undergraduate degree in biochemical sciences from Harvard College and his D.Phil. degree in theoretical chemistry from Oxford University on a Rhodes Scholarship. His postdoctoral research was on ice and water with Walter Kauzmann at Princeton and in protein crystallography with Richard Dickerson. He joined the UCLA faculty after his postdoctoral studies. Dr. Eisenberg and his research group focus on protein interactions in amyloid and prion diseases. These diseases involve protein aggregation where normal functional proteins convert to abnormal aggregated forms. Systemic amyloid diseases like dialysis-related amyloidosis result from fiber accumulation until organ failure, while neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and prion conditions appear to be caused by smaller oligomers. In 2005, his team determined the atomic-level structure for the amyloid fiber spine, revealing a 'steric zipper' of two parallel beta sheets packed across a dry interface. Since then, they've determined approximately 90 amyloid spines from 15 disease-related proteins. In 2010, they identified the structure of a toxic amyloid-related oligomer consisting of six anti-parallel beta strands forming a cylindrical barrel. His recent publications demonstrate continued innovation in amyloid research, with focus areas including structural prediction of amyloid formation, mechanisms of tau fibril disassembly in Alzheimer's disease, cryo-EM analysis of amyloid polymorphism, and structure-based design of inhibitors for amyloid toxicity. His work integrates computational, structural, and biochemical approaches to understand protein aggregation across multiple disease contexts. Dr. Eisenberg has received numerous prestigious awards and honors: National Academy of Sciences Member American Philosophical Society Member Institute of Medicine Member Howard Hughes Medical Institute Investigator Biophysical Society Emily M. Gray Award Harvard Westheimer Medal UCLA Seaborg Medal Technion - Israel Institute of Technology Harvey Prize in Human Health As Director of the UCLA-DOE Institute for Genomics and Proteomics and an HHMI Investigator, Dr. Eisenberg leads significant research initiatives in protein structure and aggregation. His laboratory combines X-ray crystallography, bioinformatics, and biochemical techniques to investigate protein interactions, with particular emphasis on amyloid-forming proteins and their role in disease. The Eisenberg Lab, located in Boyer Hall at UCLA, maintains an active research program investigating the structural basis of protein aggregation. The lab continues to build on its landmark discoveries of amyloid structures while exploring new frontiers in understanding protein misfolding diseases and developing potential therapeutic interventions.
Dr. Canan Dagdeviren is an Associate Professor and LG Career Development Professor of Media Arts and Sciences at the Massachusetts Institute of Technology, where she directs the Conformable Decoders research group at the MIT Media Lab. She joined the MIT faculty in January 2017 and has established herself as a leading innovator in conformable biomedical devices. Education: Ph.D. in Materials Science and Engineering, University of Illinois at Urbana-Champaign M.Sc. in Materials Science and Engineering, Sabanci University, Istanbul, Turkey B.Sc. in Physics Engineering, Hacettepe University, Ankara, Turkey Dr. Dagdeviren's research focuses on creating mechanically adaptive electromechanical systems that can intimately integrate with biological surfaces for sensing, actuation, and energy harvesting. She believes vital information from nature and the human body is 'coded' in various physical patterns, and her work develops 'conformable decoders' to translate these patterns into beneficial signals and energy. Her research spans wearable and implantable medical devices, with particular emphasis on piezoelectric systems that can be twisted, folded, stretched, wrapped, and implanted onto curvilinear surfaces of the human body without damage or significant alteration in performance. Analysis of her recent publications reveals a strong focus on medical applications of conformable electronics, particularly in ultrasound technology for breast cancer detection, deep brain stimulation, and bladder monitoring. Her work consistently bridges materials science, electrical engineering, and medical applications, with increasing emphasis on practical healthcare solutions that can be deployed outside clinical settings. Major Scientific Awards: NSF CAREER Award (2021) 3M Non-Tenured Faculty Award (2021) MIT Technology Review's Top 35 Innovators Under 35 (2015) Forbes' Top 30 Under 30 in Science (2015) National Academy of Engineering US Frontiers of Engineering Symposium participant (2019) Frank E. Perkins Award for Excellence in Graduate Advising Aziz Sancar Science Award Dr. Dagdeviren actively mentors graduate students and has received recognition for her advising excellence. Her research is supported by significant grants including the NSF CAREER award and has resulted in numerous patents and commercialization opportunities. She has developed innovative cleanroom-based courses at MIT that train students in microfabrication techniques for biomedical devices. The Conformable Decoders research group operates a specialized cleanroom facility at the MIT Media Lab, enabling the development and fabrication of novel conformable electronic systems. The group's work has attracted attention from major media outlets including BBC, CNN, and Nature, and has potential applications across multiple medical specialties including neurology, oncology, and urology.
David Vocadlo is a Distinguished Professor of Chemistry and Molecular Biology & Biochemistry at Simon Fraser University (SFU), holding the Canada Research Chair in Chemical Biology. His research focuses on Chemical Glycobiology, investigating carbohydrate-processing enzymes and developing chemical tools to study glycan roles in health and disease. His lab explores O-GlcNAc signaling, neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s), and enzyme inhibitors for therapeutic applications. Education: PhD from University of British Columbia (UBC), followed by a CIHR postdoctoral fellowship at UC Berkeley. Key roles include E.W.R. Steacie Memorial Fellow and Royal Society Fellow. Research highlights include O-GlcNAcase inhibitors for neuroprotection, glycan structure-function relationships, and enzyme activity imaging tools. Collaborates globally with experts in glycobiology and employs cutting-edge techniques like chemical synthesis, mass spectrometry, and live-cell imaging. Awards: Distinguished Professor title, Canada Research Chair, Royal Society Fellowship. Active in training researchers through SFU’s graduate programs, emphasizing interdisciplinary approaches. Lab members work on topics ranging from enzyme mechanisms to disease modeling.
Weiqiang Chen is a Professor of Mechanical and Biomedical Engineering at New York University's Tandon School of Engineering and Director of Research and PhD Programs. He holds a joint appointment at NYU Langone's Perlmutter Cancer Center as a Faculty Member of the Tumor Immunology Research Program. B.S. in Physics (Nanjing University, 2005) M.S. in Electrical Engineering (Shanghai Jiao Tong University, 2008) M.S. in Electrical and Computer Engineering (Purdue University, 2009) Ph.D. in Mechanical Engineering (University of Michigan, 2014) His research focuses on Lab-on-a-Chip , Organ-on-Chip systems, Biomaterials , and Mechanobiology , with applications in cancer biology, stem cell engineering, and immune monitoring. He pioneers microfabrication technologies for real-time observation of cellular interactions, including CAR T-cell immunotherapy efficacy and tumor microenvironment dynamics. Recent grants include NSF funding for leukemia bone marrow niche modeling, NIH Trailblazer Awards for glioblastoma immunotherapy research, and collaborations with the Arthritis Foundation for synovium-on-chip rheumatoid arthritis studies. His work has been supported by over $2M in federal and institutional research funding. National Science Foundation (NSF) grants for leukemia-on-chip and glioblastoma modeling National Institutes of Health (NIH) awards for immunotherapy research American Heart Association fellowships and institutional training programs Chen's scientific awards include the American Heart Association Fellow distinction, multiple Young Investigator Awards from Lab on a Chip and Biomedical Engineering Society, and recognition for his dissertation on nanotopography in stem cell differentiation. He leads the Applied Micro-Bioengineering Laboratory (AMBL) , which develops microphysiological systems for drug testing and personalized medicine. His team has created the first immunocompetent leukemia-on-a-chip for CAR T-cell therapy screening and glioblastoma models that enable patient-specific immunotherapy validation.
Professor Urs Jenal is a Full Professor at the Biozentrum of the University of Basel, Switzerland, where he has led research on bacterial signal transduction since 2008. His laboratory investigates the molecular mechanisms of bacterial persistence and antibiotic resistance, with particular focus on pathogens causing chronic infections in humans. Previously, he served as Associate Professor (2002-2008) and Assistant Professor (1996-2002) at the same institution, and completed postdoctoral training at Stanford University and ETH Zurich. Education 2000: Habilitation and VENIA DOCENDI in Microbiology, University of Basel 1987-1991: PhD in Molecular Microbiology, ETH Zurich (supervisor: Prof. T. Leisinger) 1982-1986: Studies of Experimental Biology, ETH Zurich 1977-1981: Gymnasium with Matura Type C, Chur Research Focus Prof. Jenal's research centers on understanding how bacterial pathogens persist in the human body despite antibiotic treatments. His laboratory investigates cyclic nucleotides, particularly c-di-GMP, as signaling molecules that control bacterial biofilm formation, virulence, and antibiotic tolerance. His team studies pathogenic Escherichia coli causing recurrent urinary tract infections and Pseudomonas aeruginosa causing long-term lung infections in cystic fibrosis patients. Recent work has revealed how "sleeping" bacteria survive antibiotic treatments and how pathogens breach respiratory epithelia through goblet cell invasion. Scientific Recognition 2014: Elected member of the European Academy of Microbiology (EAM) 2013: ERC Advanced Investigator Award 2012: Elected member of the European Molecular Biology Organization (EMBO) 2011: Elected member of the American Academy of Microbiology (AAM) Mentorship and Collaborations Prof. Jenal has mentored numerous PhD students and postdocs, many receiving awards for their research. His laboratory is part of the NCCR AntiResist initiative focused on developing novel approaches against antibiotic resistance. He collaborates extensively with clinical researchers and has developed innovative models, including human mini-lungs, to investigate pathogen-host interactions. His recent publications demonstrate how understanding bacterial persistence mechanisms can lead to new therapeutic strategies against chronic infections.
Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788
Magdy M. A. Salama is a Professor and University Research Chair at the University of Waterloo's Department of Electrical and Computer Engineering, Faculty of Engineering. He holds a P.Eng. license and is a Fellow of the IEEE. His research spans Energy Systems (Power Quality, Smart Grids, Renewable Energy) and Biomedical Engineering (Medical Imaging, Sleep Analysis). He has authored/co-authored over 460 publications and supervised numerous graduate students. Education: PhD (University of Waterloo), M.Sc. and B.Sc. (Cairo University). Awards include the IEEE Fellow distinction, University Research Chair, and multiple teaching/research awards from the University of Waterloo. Research trends in his articles focus on Smart Grid resiliency, renewable integration, cyber-physical security, and biomedical applications of AI. Notable projects include voltage sag mitigation, EV fleet electrification, and blockchain-based energy trading platforms. Scientific Awards: IEEE Fellow, University Research Chair, Teaching Excellence Award (2000) Grants/Consultation: Extensive industry and institutional collaborations on power systems and biomedical tech. Labs/Teams: Active in High Voltage Lab, Smart Grids Research Group, and Medical Image Processing Lab.
Prof. Dr. Deniz Tasdemir is a Full Professor (W3) of Marine Natural Products Chemistry at GEOMAR Helmholtz-Zentrum für Ozeanforschung Kiel and serves as Director of the GEOMAR-Biotech center and Head of the Marine Natural Product Chemistry Research Unit. Her career spans institutions including the National University of Ireland Galway and UCL School of Pharmacy. PhD in Pharmacy, ETH Zurich (1997) Post-doctoral work, University of Utah (2001) Dr. Helmut Legerlotz Fellowship, University of Zurich (2002-2025) Her research focuses on marine chemical ecology , metabolomics , and bioprospecting for bioactive compounds from sponges, algae, and marine microbiomes. Recent work explores seagrass pathogen reduction, microbiome interactions, and aquafeed applications. Scientific awards include: Waters Award for Natural Products Innovation (2016) Egon Stahl Silver Medal (2005) Pierre Fabre Prize (2004) ETH Zurich Medal (1997) She leads collaborative projects on ocean sustainability and marine drug discovery, with editorial roles in Marine Drugs , Planta Medica , and Phytochemistry Letters .
